BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Quelle est la performance du prix de l'action BioSyent Inc. ?
Le prix actuel de BioSyent Inc. est de $11.24, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de BioSyent Inc. ?
BioSyent Inc. appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de BioSyent Inc. ?
La capitalisation boursière actuelle de BioSyent Inc. est de $129.2M
Est-ce que BioSyent Inc. est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour BioSyent Inc., y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte